IP Library Patent Application 15456004
Patent Application
App. No. 15/456,004

DRY POWDER FIBRIN SEALANT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/456,004
Abstract

The invention provides a composition comprising a mixture of first microparticles that comprise fibrinogen and trehalose, and second microparticles that comprise thrombin and trehalose. The invention further provides methods for treating wounds by administering the novel microparticle composition.

Claims (25)

1 . A dry powder fibrin sealant composition, comprising:

a mixture of first microparticles that comprise 0.5 to 20% w/w fibrinogen and trehalose, and second microparticles that comprise 10 to 20,000 IU/g thrombin and trehalose,

wherein trehalose is the only stabilizing sugar in the first microparticles and second microparticles.

2 . The composition of claim 1 , wherein the composition is sterilizable by gamma irradiation.

3 . The composition of claim 2 , wherein the concentration of trehalose in the first microparticles is sufficient to preserve at least 70% of fibrinogen activity after exposure of the first microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

4 . The composition of claim 3 , wherein fibrinogen activity is measured by ELISA.

5 . The composition of claim 2 , wherein the first microparticles have a bioactivity of at least 10 mg fibrinogen per 100 mg microparticles after exposure to gamma irradiation.

6 . The composition of claim 2 , wherein the second microparticles have a bioactivity of at least 70 units thrombin per 100 mg microparticles after exposure to gamma irradiation.

7 . The composition of claim 5 , wherein the bioactivity is measured by ELISA.

8 . The composition of claim 6 , wherein the bioactivity is measured by chromogenic assays.

9 . The composition of claim 1 , wherein the mixture of first microparticles and second microparticles has a clot strength of at least 50 g after exposure to gamma irradiation.

10 . The composition of claim 1 , wherein the concentration of trehalose in the first microparticles and second microparticles is sufficient to preserve at least 70% of expected clot strength after exposure of the mixture of microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

11 . The composition of claim 1 , wherein the microparticles are spray-dried microparticles.

12 . The composition of claim 11 , wherein the composition has a residual moisture content no greater than 5% (w/w).

13 . The composition of claim 12 , wherein the residual content is no great than 3% (w/w).

14 . The composition of claim 1 , wherein said first and second microparticles are mixed in a weight ratio of 1:1.

15 . A method for preparing a dry powder fibrin sealant composition comprising a mixture of first microparticles that comprise 0.5 to 20% w/w fibrinogen and trehalose and second microparticles that comprise 10 to 20,000 IU/g thrombin and trehalose, wherein trehalose is the only stabilizing sugar in the first microparticles and second microparticles, the method comprising:

(i) spray-drying a first aqueous solution comprising fibrinogen and trehalose to produce said first microparticles, wherein said first aqueous solution does not include a second stabilizing sugar;

(ii) spray-drying a second aqueous solution comprising thrombin and trehalose to produce said second microparticles, wherein said second aqueous solution does not include a second stabilizing sugar; and

(iii) mixing the first and second microparticles.

16 . The method of claim 15 , wherein the first microparticles have at least 70% of fibrinogen activity after exposure of the first microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

17 . The method of claim 15 , wherein the mixture of the first and second microparticles preserves at least 70% of expected clot strength after exposure of the mixture of microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

18 . The method of claim 15 , wherein each of the first and second aqueous solutions is spray-dried with an outlet temperature of at least about 80° C.

19 . The method of claim 15 , wherein the dry powder fibrin sealant composition has a residual moisture content no greater than 5% (w/w).

20 . The method of claim 15 , wherein step (iii) comprises mixing the first and second microparticles in a weight ratio of 1:1.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0213 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0542 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049823/0213 →